Lornit 150 Tablet contains L-Ornithine L-Aspartate 150 mg, a compound utilized primarily in the management of hepatic encephalopathy and other liver-related disorders. L-Ornithine L-Aspartate acts by enhancing the urea cycle, facilitating the detoxification of ammonia, a neurotoxic substance that accumulates in patients with liver dysfunction. This mechanism helps reduce elevated blood ammonia levels, thereby improving cognitive function and overall neurological status in affected individuals. Lornit 150 is indicated as an adjunct therapy in chronic liver diseases such as cirrhosis, where it aids in the prevention and treatment of hepatic encephalopathy episodes. The tablet is generally well-tolerated, with a favorable safety profile when administered as prescribed. Dosage and duration of treatment should be individualized based on the severity of the condition and patient response, under medical supervision. It is contraindicated in patients with known hypersensitivity to any component of the formulation. Caution is advised in patients with renal impairment, and monitoring of liver function tests is recommended during prolonged therapy. Lornit 150 should be used as part of a comprehensive treatment plan including dietary management and other supportive measures to optimize liver health and patient outcomes.